Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

NCT03296553 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER_GOV

Sponsor class

Conditions

Kaposi Sarcoma
Human Immunodeficiency Virus
Immune Reconstitution Syndrome

Interventions

DRUG: Valganciclovir
DRUG: Antiretroviral Combinations

Sponsor

National Institute of Cancerología

Collaborators

[object Object]